Will Paragon 28 Stock Gain From the Latest Product Launch of R3FLEX?
In This Article:
Paragon 28, Inc. FNA recently launched the R3FLEX Stabilization System, designed to restore stability to the ankle syndesmosis after suffering an injury from an ankle fracture or high ankle sprain.
The latest innovation is aimed at strengthening the company’s syndesmotic injury repair portfolio. As predicted, the R3FLEX Stabilization System will be used to treat 470 million ankle fractures in the United States in 2024.
Following the launch, shares of Paragon 28 lost 12% on Friday. However, as FNA is gaining a high level of synergies from its continuously expanding product portfolio within the promising foot and ankle soft tissue industry, this latest development might prove fruitful in strengthening the company’s foothold in this space. Accordingly, we expect market sentiment to recover shortly.
About Paragon 28’s R3FLEX Stabilization System
The design and functionality of the system allow surgeons to restore patients’ soft tissue to a more natural anatomy, helping mitigate arthritic response and minimize the risk of hardware removal.
The R3FLEX Stabilization System is delivered to surgeons in a single sterile kit, which includes both the implants and instruments to simplify surgical workflow and inventory management. The R3FLEX implant comes with a short suture loop between the all-suture anchor in the tibia and the titanium fibular component. It is designed to create a strong repair construct that is less susceptible to elongation or creep.
During preparation and implantation of the implant, the tibial implant rests on the internal surface. The fixation on the lateral tibial cortex decreases the potential for interference with medial tibial fracture hardware or injury to medial distal tibial neurovasculature.
More on Paragon 28’s Product Portfolio
FNA’s soft tissue offering includes the Grappler Suture Anchor System, the Grappler Knotless Anchor System and the Bridgeline Tape. Additionally, the company offers the Grappler Interference Screw System, the Grappler R3INFORCE Extraosseous Repair System, the R3ACT Stabilization System and the R3LEASE Stabilization System. The Paratrooper Plantar Plate System, the TenoTac 2.0 Soft Tissue Fixation System and the Mister Tendon Harvester System are also some of FNA’s products.
With this comprehensive portfolio, Paragon 28 provides its customers with a single source to address their foot and ankle soft tissue needs.
Industry Prospects Favors Paragon 28
Per a Persistence Market Research report, the global ankle syndesmotic treatment device market was valued at $157.1 million in 2022 and is expected to reach $355.2 million by 2033 at a CARG of 7.7% during the period.
